Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
By François Ghiringhelli, C. Ménard, P. Puig, S. Ladoire, S. Roux, F. Martin, E. Solary, A. Le Cesne, L. Zitvogel, B. Chauffert. Cancer Immunology and Immunotherapy, 2007
1,275 citations recorded by the source corpus.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/ec325831284e26302a0796f84448bc1e1bb27278
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Guido Kroemer
- L. Galluzzi
- L. Zitvogel
- Oliver Kepp
- A. Buqué
- C. Sautès-Fridman
- Franck Pagès
- A. Tesnière
Citations in the corpus
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies (2015, background): “Clinically, cyclophosphamide doses of 200 to 300 mg/m(2) given 1 day prior to vaccination or 600 mg/m(2) given 7 days prior to vaccination can decrease Tregs; metronomic cyclophosphamide is similarly effective (42, 43).”
- The secret ally: immunostimulation by anticancer drugs (2012, background): “, low-dose cyclophosphamide selectively suppresses inhibitory cell subsets including MDSCs and T reg cells (which facilitate IFNγ-mediated anticancer immunity”
- Immune infiltration in human tumors: a prognostic factor that should not be ignored (2010, background): “This does not, however, eliminate the possibility that immunemodifying chemotherapies that stimulate the immune system (Tesniere et al., 2008) or inhibit T reg (Ghiringhelli et al., 2007) may eventually modify the immune contexture of primary or metastatic tumors.”
- Immune parameters affecting the efficacy of chemotherapeutic regimens (2011, background): “For example, low metronomic doses of cyclophosphamide (usually 50 mg/day for 3 weeks or a single 300 mg/m 2 dose) selectively deplete and/or inhibit regulatory T cells (T REG ), which have immunosuppressive properties”
- Cancer despite immunosurveillance: immunoselection and immunosubversion (2006, background): “For example, low doses of cyclophosphamide can selectively deplete and inhibit T Reg cells, thereby restoring normal CTL and NK-cell function in patients with cance”
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “(which means, low doses administered in a repetitive fashion) depletes TREG cells in humans (resulting in the restoration of T and NK cell functions), (Ghiringhelli et al., 2007), most likely because these cells lack ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1), which normally extr”